tirzepatide phase 2 Tirzepatide: A First-in-class Twincretin for the Management of Type Diabetes Patients who took the anti-obesity

While these observational data cannot definitively establish causality and may be subject to residual confounding despite sophisticated analytical approaches, the consistency of findings across multiple large, geographically diverse cohorts using different methodologies substantially strengthens confidence in the hepatoprotective benefits of GLP-1-based therapies

Stergiakouli E, Thapar A, Davey Smith G

Several papers have reported and discussed the intermolecular interactions of gold nanoparticles and glutathione

No robust clinical trials demonstrate that any probiotic strain prevents GLP-1-related nausea specifically